Strategy for second kidney biopsy in patients with lupus nephritis

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1472-1478

  Alsuwaida, Abdulkareem ^a   Husain, Sufia ^a   Alghonaim, Mohammed ^a   Aloudah, Noura ^a   Alwakeel, Jamal ^a   Ullah, Anhar ^a   Kfoury, Hala ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

kidney biopsy; lupus nephritis; systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REPEAT PROCEDURE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; REOPERATION; SURVIVAL RATE;

EID: 84859308909     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr517     Document Type: Article

References (27)

1. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940 (Pubitemid 39643941)
2. Gladman DD, Urowitz MB, Cole E et al. Kidney biopsy in SLE: I. A clinical-morphologic evaluation. Q J Med 1989; 73: 1125-1133 (Pubitemid 20019606)
3. Nossent JC, Henzen-Logmans SC, Vroom TM et al. Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int 1991; 11: 77-82
4. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-161 (Pubitemid 32410070)
5. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
6. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277 (Pubitemid 13221242)
7. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250 (Pubitemid 38140764)
8. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530 (Pubitemid 38130646)
9. Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63: 537-550
10. Austin HA III, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695 (Pubitemid 14079965)
11. Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53
12. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980 (Pubitemid 38269274)
13. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228 (Pubitemid 41697285)
14. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510 (Pubitemid 41727277)
15. Daleboudt GM, Bajema IM, Goemaere NN et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: 3712-3717
16. Chan TM. Preventing renal failure in patients with severe lupus nephritis. Kidney Int Suppl 2005; 94: S116-S119
17. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney Int 1994; 45: 544-550 (Pubitemid 24065091)
18. Nossent HC, Henzen-Logmans SC, Vroom TM et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Arthritis Rheum 1990; 33: 970-977 (Pubitemid 20226350)
19. Arce-Salinas CA, Villa AR, Martinez-Rueda JO et al. Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 1995; 4: 197-203
20. Appel GP, Cohen DJ, Pirani CL et al. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885 (Pubitemid 18098162)
21. Levey AS, Lan S-P, Corwin HL et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 114-123
22. Valeri A, Radhakrishnan J, Estes D et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective fiveyear study. Clin Nephrol 1994; 42: 71-78 (Pubitemid 24247185)
23. Hill GS, Delahousse M, Nochy D et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001; 59: 304-316 (Pubitemid 32063019)
24. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renalallograft rejection by measurement of messenger RNA for perforin and granzyme B urine. N Engl J Med 2001; 344: 947-954 (Pubitemid 32240312)
25. Hu H, Aizenstein BD, Puchalski A et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432-437 (Pubitemid 38282301)
26. Tatapudi RR, Muthukumar T, Dadhania D et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390-2397 (Pubitemid 38670025)
27. Schaub S, Rush D, Wilkins J et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15: 219-227 (Pubitemid 38020714)